- Home
- OSUR vs RCEL Comparison
OSUR vs RCEL Comparison
Compare OSUR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- RCEL
- Stock Information
- Founded
- OSUR 2000
- RCEL 2020
- Country
- OSUR United States
- RCEL United States
- Employees
- OSUR N/A
- RCEL N/A
- Industry
- OSUR Medical/Dental Instruments
- RCEL Medical/Dental Instruments
- Sector
- OSUR Health Care
- RCEL Health Care
- Exchange
- OSUR Nasdaq
- RCEL Nasdaq
- Market Cap
- OSUR 289.4M
- RCEL 308.6M
- IPO Year
- OSUR 1986
- RCEL N/A
- Fundamental
- Price
- OSUR $3.92
- RCEL $8.73
- Analyst Decision
- OSUR Hold
- RCEL Buy
- Analyst Count
- OSUR 2
- RCEL 5
- Target Price
- OSUR $5.50
- RCEL $18.00
- AVG Volume (30 Days)
- OSUR 914.1K
- RCEL 251.2K
- Earning Date
- OSUR 02-25-2025
- RCEL 02-13-2025
- Dividend Yield
- OSUR N/A
- RCEL N/A
- EPS Growth
- OSUR N/A
- RCEL N/A
- EPS
- OSUR 0.15
- RCEL N/A
- Revenue
- OSUR $224,263,000.00
- RCEL $60,040,000.00
- Revenue This Year
- OSUR N/A
- RCEL $36.71
- Revenue Next Year
- OSUR N/A
- RCEL $54.48
- P/E Ratio
- OSUR $25.69
- RCEL N/A
- Revenue Growth
- OSUR N/A
- RCEL 32.24
- 52 Week Low
- OSUR $3.52
- RCEL $7.51
- 52 Week High
- OSUR $8.04
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- OSUR 57.58
- RCEL 31.80
- Support Level
- OSUR $3.52
- RCEL $8.53
- Resistance Level
- OSUR $3.80
- RCEL $9.42
- Average True Range (ATR)
- OSUR 0.14
- RCEL 0.65
- MACD
- OSUR 0.03
- RCEL -0.39
- Stochastic Oscillator
- OSUR 93.02
- RCEL 3.89
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.